Is NAD+ a Peptide? NAD vs Peptides Explained

PrescribedRX is a telehealth platform; prescriptions are written by licensed clinicians and filled by licensed partner pharmacies.

Short answer: No. NAD+ (nicotinamide adenine dinucleotide) is a coenzyme made of two nucleotide units joined by phosphate groups, while a peptide is a short chain of amino acids. NAD+ gets called a “peptide” because clinics and online sellers offer it on the same menus, in the same kind of vials and from the same compounding pharmacies as true peptides, not because of its chemistry.

Is NAD+ a peptide? The short answer

No. The National Human Genome Research Institute defines a peptide as “a short chain of amino acids (typically 2 to 50) linked by chemical bonds (called peptide bonds).” A chain of 51 or more amino acids is a polypeptide, and proteins are made from one or more polypeptides (NHGRI glossary).

NAD+ has no amino acids at all. PubChem lists its formula as C21H27N7O14P2 with a molecular weight of 663.4. It describes NAD+ as a coenzyme built from two nucleotide halves, one carrying nicotinamide and one carrying adenine, linked by a pyrophosphate (double phosphate) bond (PubChem CID 5892). There are no peptide bonds anywhere in the molecule.

How does NAD+ compare with a peptide, side by side?

Think of a peptide as beads on a string, each bead an amino acid. NAD+ is two small units clipped together by phosphates. Semaglutide, a peptide drug, is the comparison.

	NAD+	A peptide (example: semaglutide)
What it is	Coenzyme (a dinucleotide)	Short chain of amino acids
Building blocks	Nicotinamide, adenine, two ribose sugars, two phosphates	Amino acids
What holds it together	A pyrophosphate (phosphate) link	Peptide bonds
Size	663.4 (PubChem)	4,113.58 g/mol (Wegovy label)
Main job	Carries electrons in many enzyme reactions and donates ADP-ribose	Semaglutide acts on the GLP-1 receptor
FDA status	No FDA-approved NAD+ product; compounded NAD+ is not FDA approved	FDA approved as Wegovy; compounded semaglutide is not FDA approved

Sources: PubChem, the Wegovy prescribing information and FDA on compounded drugs. NAD+ is a helper molecule inside cells, not a signal sent to a receptor.

For a true peptide that PrescribedRX lists under its longevity plans, see our sermorelin therapy guide.

Why is NAD+ called a peptide?

Mostly because of how it is sold. Clinics often package NAD+ inside “peptide therapy” programs, it comes in the same kind of vial, and the same online stores sell both. The label stuck to the menu, not the molecule.

Some of those stores label products “research use only.” In an August 24, 2026 warning letter to TXP Innovations LLC (doing business as Tex Peptides), FDA wrote that despite such statements, evidence from the company’s website showed its products were intended to be drugs for human use (FDA warning letter). The letter named peptides such as semaglutide and tirzepatide, not NAD+.

The oral supplements NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) also get called “NAD peptides.” They are NAD+ precursors, which the body uses to make NAD+, not peptides.

Is NAD+ FDA approved, and does the peptide label matter?

It matters for regulation. FDA sorts substances nominated for 503A compounding into categories while it evaluates them (FDA 503A bulk drug substances page). NAD+ sits in Category 1, which FDA describes as substances that “may be eligible for inclusion on the 503A bulks list.”

Category 1 is a compounding policy, not an approval or proof that NAD+ works or is safe. There is no FDA-approved NAD+ product by any route. Our page on NAD+’s FDA regulatory record goes through the full history, and our peptide compounding status tracker follows the substances that really are peptides.

NAD+ injection vs nasal spray vs NMN and NR: how strong is the evidence?

In 2026, a systematic review in Ageing Research Reviews pulled together 113 studies, including 33 human intervention studies (Gallagher and Emmanuel, 2026). Its findings shape the table below.

Form	What it is	Human studies cited on this page
IV NAD+	NAD+ itself, infused	One small pilot that measured blood and urine levels; the 2026 review found no outcome trials
NAD+ injection (under the skin or into muscle)	NAD+ itself	The 2026 review found no outcome trials of intramuscular NAD+; we found none for under-the-skin use
NAD+ nasal spray	NAD+ itself	We found no published human study; one 2026 study in cells and mice
Oral NR	NAD+ precursor	Randomized trials reported raised NAD+ markers; the 2026 review calls outcome effects “heterogeneous and often null”
Oral NMN	NAD+ precursor	Small randomized trials; one reported a change in muscle insulin sensitivity in a narrow group; a 2025 meta-analysis reported no significant effect on muscle measures

• IV NAD+. A 2019 pilot followed people during a 6-hour infusion. At the rate used, NAD+ was “rapidly and completely removed from the plasma for at least the first 2 h” (Grant et al., 2019). It measured metabolism, not symptoms or outcomes.
• Injection under the skin or into muscle. The 2026 review found that “no eligible outcomes trials evaluated intravenous or intramuscular NAD+ itself for anti-aging or wellness indications” (Ageing Res Rev, 2026). Our summary of what the research on NAD+ injections shows goes deeper.
• Nasal spray. We found no published human study. The one 2026 intranasal NAD paper used human stem cells in a dish and mice with induced loss of smell (Yoo et al., 2026). Those were cell and animal results, not results in people. See our NAD+ nasal spray evidence review.
• Oral NR. A randomized, double-blind crossover trial (two 6-week periods) reported that NR was well tolerated and stimulated NAD+ metabolism in healthy middle-aged and older adults. Effects on blood pressure were flagged for future trials, not proven (Martens et al., 2018).
• Oral NMN. A 10-week randomized trial in postmenopausal women with prediabetes and overweight or obesity reported that NMN increased muscle insulin sensitivity (Yoshino et al., 2021). A 2025 meta-analysis found NMN had no significant effect on muscle mass, grip strength or gait speed in older adults (Prokopidis et al., 2025).

Overall, oral NR and NMN “consistently demonstrated biochemical target engagement,” meaning they raised NAD+-related markers, but effects on health outcomes were “heterogeneous and often null or endpoint-specific.” The review concluded that clinical effectiveness for anti-aging or wellness outcomes “remains inconclusive.” Oral precursor results do not tell us what injections or nasal spray do. For more, read IV vs injection vs nasal NAD+.

What is NAD+ not proven to do?

The 2026 systematic review concluded that NAD+ augmentation “shows clear biological activity, but clinical effectiveness for anti-aging or wellness outcomes remains inconclusive.” It found no eligible outcome trials of IV or intramuscular NAD+ itself (Ageing Res Rev, 2026).

• Anti-aging or wellness outcomes in general: “inconclusive”
• Functional, metabolic, vascular and other healthspan outcomes with oral NR and NMN: “heterogeneous and often null or endpoint-specific”
• IV or intramuscular NAD+ itself: no eligible outcome trials

“Inconclusive” does not mean “proven not to work.” The authors call for larger, well-designed randomized trials with longer follow-up, particularly for injected and infused approaches.

How do PrescribedRX NAD+ plans work?

PrescribedRX offers two forms through its longevity plans for NAD+, sermorelin and glutathione. Both are compounded, and compounded NAD+ is not FDA approved.

• Compounded NAD+ injection, 200 mg/mL, 6 mL vial (not FDA approved)
• NAD+ nasal spray plan, 200 mg/mL, 6 mL (compounded, not FDA approved)

You complete an online intake, and a licensed provider reviews it, typically within 48 hours. A prescription is issued only if a licensed provider determines treatment is appropriate. State-licensed clinicians prescribe through Telegra MD, and licensed partner pharmacies fill the order. Plans are self-pay, priority shipping is included, and availability varies by state. Your provider sets the dose.

Prices as shown on prescribedrx.com in October 2026 (see what every PrescribedRX treatment costs):

Plan	Monthly	3 months	FDA status
NAD+ Injection 200 mg/mL, 6 mL	Monthly plan $169 a month	3 month plan $412 · $137/mo · Billed every 10 weeks. Cancel anytime.	Compounded, not FDA approved
NAD+ Nasal Spray 200 mg/mL, 6 mL	Monthly plan $169 a month	3 month plan $412 · $137/mo · Billed every 10 weeks. Cancel anytime.	Compounded, not FDA approved

When should you talk to a doctor?

Our NAD+ side effects page covers what is reported by route. If you have symptoms after any treatment, talk to a licensed provider.

Talk to a licensed provider about your health history and any supplements you take, such as NMN, NR or niacin.

Frequently asked questions

Is an NAD+ injection the same as taking NMN or NR?

No. An injection gives NAD+ itself, while NMN and NR are oral precursors your body uses to make NAD+. The randomized human trials cited here are for oral NR and NMN, which reported raised NAD+ markers in blood. The 2026 review found no eligible outcome trials of IV or intramuscular NAD+ itself (Ageing Res Rev, 2026).

Can I take NAD+ and peptides at the same time?

That is a decision for your provider, based on your history and what you already take. We found no trials testing NAD+ combined with peptides. Tell your provider about every injection, prescription and supplement you use.

Is IV NAD better than NMN supplements?

We found no study comparing them. IV NAD+ has one small pilot that measured blood and urine levels, and the 2026 review found no outcome trials. Oral NMN has small randomized trials reporting raised NAD+ markers. The 2026 review concluded that clinical effectiveness for anti-aging or wellness outcomes “remains inconclusive” (Ageing Res Rev, 2026).

What does NAD+ do in the body?

NAD+ is a coenzyme. According to PubChem, it carries electrons in many enzyme reactions, switching between its NAD+ and NADH forms, and donates ADP-ribose groups. It works as a helper molecule inside cells, not as a signal acting on a receptor the way semaglutide does.

How does a provider review for NAD+ work?

A licensed provider reviews your intake, typically within 48 hours, and a prescription is issued only if a licensed provider determines treatment is appropriate. NAD+ injection or nasal spray: Monthly plan $169 a month Or 3 month plan $412 · $137/mo · Billed every 10 weeks. Cancel anytime. Compounded NAD+ is not FDA approved. Your provider sets the dose.

Check your eligibility or explore longevity plans.

Sources

1. National Human Genome Research Institute. Peptide, Talking Glossary of Genomic and Genetic Terms. genome.gov. Accessed Oct 2026.
2. PubChem, National Library of Medicine. Nadide (NAD+), CID 5892. pubchem.ncbi.nlm.nih.gov. Accessed Oct 2026.
3. DailyMed, National Library of Medicine. WEGOVY (semaglutide) prescribing information. dailymed.nlm.nih.gov. Accessed Oct 2026.
4. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (content current as of May 14, 2026). fda.gov. Accessed Oct 2026.
5. U.S. Food and Drug Administration. Human Drug Compounding. fda.gov. Accessed Oct 2026.
6. Gallagher C, Emmanuel OO. NAD+ supplementation for anti-aging and wellness: a PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Res Rev. 2026;116:103057. PubMed. Accessed Oct 2026.
7. Grant R, et al. A pilot study investigating changes in the human plasma and urine NAD+ metabolome during a 6 hour intravenous infusion of NAD. Front Aging Neurosci. 2019;11:257. PubMed. Accessed Oct 2026.
8. Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9:1286. PubMed. Accessed Oct 2026.
9. Yoshino M, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372:1224-1229. PubMed. Accessed Oct 2026.
10. Prokopidis K, et al. The effect of nicotinamide mononucleotide and riboside on skeletal muscle mass and function: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2025;16(3):e13799. PubMed. Accessed Oct 2026.
11. Yoo SH, et al. Therapeutic effect of intranasal nicotinamide adenine dinucleotide in the restoration of olfactory dysfunction. Exp Mol Med. 2026;58(7):2155-2167. PubMed. Accessed Oct 2026.
12. U.S. Food and Drug Administration. Warning Letter, TXP Innovations LLC dba Tex Peptides (Aug 24, 2026). fda.gov. Accessed Oct 2026.

This article is for general information. It is not medical advice and it is not a recommendation for any particular treatment. Whether a treatment is appropriate for you is a decision for a licensed clinician who has reviewed your health history and current medications.